Cancer Drug Parity Act of 2019
Bill journey · stage 2 of 5
Under committee review
What it doesSummary introduced in house (Mar 13, 2019)
Cancer Drug Parity Act of 2019
This bill requires health plans that cover anticancer medications administered by a health care provider to provide no less favorable cost sharing for patient-administered anticancer medications. This requirement applies to medications that are (1) approved by the Food and Drug Administration; (2) medically necessary for the cancer treatment; and (3) clinically appropriate in terms of type, frequency, extent site, and duration.
To comply with this requirement, health plans may not, with respect to anticancer medications (1) change or replace benefits to increase out-of-pocket costs, (2) reclassify benefits to increase costs, or (3) apply more restrictive limitations to orally administered medications than to intravenously administered or injected medications.What just happenedMar 14, 2019
Referred to the Subcommittee on Health.
Who’s behind it
- Introduced in HouseMar 13, 2019
- Mar 14, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Mar 13, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Mar 13, 2019IntroReferralIntro-H
Introduced in House
- Mar 13, 2019IntroReferral1000
Introduced in House